{"id":"experimental-doxycycline","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Photosensitivity"},{"rate":"5-10","effect":"Nausea and vomiting"},{"rate":"1-5","effect":"Esophageal irritation"},{"rate":"1-5","effect":"Vaginal candidiasis"},{"rate":"2-5","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxycycline is a tetracycline antibiotic that works by blocking bacterial protein synthesis through reversible binding to the bacterial 30S ribosomal subunit. This prevents the attachment of aminoacyl-tRNA to the ribosome, thereby inhibiting peptide chain elongation. The drug is bacteriostatic, meaning it stops bacterial growth rather than directly killing the organisms.","oneSentence":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:00.132Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Emerging infectious diseases (investigational indication under ANRS Phase 3 trial)"}]},"trialDetails":[{"nctId":"NCT06120140","phase":"PHASE2","title":"Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-02-16","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":300},{"nctId":"NCT07290244","phase":"PHASE1","title":"Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)","status":"RECRUITING","sponsor":"Life Biosciences Inc.","startDate":"2026-03-02","conditions":"Open Angle Glaucoma (OAG), NAION( Non-arteritic Anterior Ischemic Optic Neuropathy)","enrollment":18},{"nctId":"NCT04067011","phase":"PHASE2","title":"Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study","status":"COMPLETED","sponsor":"Emergent BioSolutions","startDate":"2019-08-12","conditions":"Anthrax","enrollment":210},{"nctId":"NCT07146139","phase":"NA","title":"MyPrEP Plus: Development and Pilot Testing of Novel Preexposure Prophylaxis Decision Support Tools for Transgender Women","status":"TERMINATED","sponsor":"Public Health Foundation Enterprises, Inc.","startDate":"2023-03-18","conditions":"HIV Pre-exposure Prophylaxis, HIV Prevention and Care, Mobile Health Technology (mHealth)","enrollment":2},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT07064278","phase":"NA","title":"Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children","status":"COMPLETED","sponsor":"Children's Hospital of Hebei Province","startDate":"2022-12-01","conditions":"Refractory Mycoplasma Pneumoniae Pneumonia","enrollment":260},{"nctId":"NCT04597424","phase":"PHASE3","title":"Combined Prevention of Sexually Transmitted Infections (STIs) in Men Who Have Sex With Men and Using Oral Tenofovir Disoproxil Fumarate/ Emtricitabine (TDF/FTC) for HIV Pre-Exposure Prophylaxis (PrEP)","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2021-01-19","conditions":"Unsafe Sex, Risk-Taking","enrollment":556},{"nctId":"NCT03474458","phase":"PHASE2, PHASE3","title":"A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy","status":"TERMINATED","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2019-02-11","conditions":"Cardiac AL Amyloidosis","enrollment":19},{"nctId":"NCT03479502","phase":"PHASE4","title":"Intra-articular Doxycycline: A Novel Treatment of Adhesive Capsulitis","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-03-05","conditions":"Adhesive Capsulitis, Adhesive Capsulitis of Unspecified Shoulder, Frozen Shoulder","enrollment":1},{"nctId":"NCT04850313","phase":"NA","title":"Evaluating the Use of ProKera Plus® in the Management of Bacterial Corneal Ulcers","status":"TERMINATED","sponsor":"University of Arkansas","startDate":"2021-11-09","conditions":"Bacterial Corneal Ulcer","enrollment":3},{"nctId":"NCT03558984","phase":"PHASE3","title":"D-PLEX 302: Efficacy and Safety of D-PLEX in the Prevention of Sternal Infection Post Cardiac Surgery","status":"TERMINATED","sponsor":"PolyPid Ltd.","startDate":"2019-12-17","conditions":"Surgical Site Infection, Sternal Infection, Cardiac Surgery","enrollment":2},{"nctId":"NCT05007223","phase":"","title":"Skin Microbiome Profile in Hailey-Hailey Disease","status":"COMPLETED","sponsor":"Gangnam Severance Hospital","startDate":"2020-05-08","conditions":"Hailey-Hailey Disease","enrollment":18},{"nctId":"NCT04370782","phase":"PHASE4","title":"Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting","status":"COMPLETED","sponsor":"St. Francis Hospital, New York","startDate":"2020-04-28","conditions":"COVID-19","enrollment":18},{"nctId":"NCT01783106","phase":"PHASE2","title":"Antibiotics and Hydroxychloroquine in Crohn's","status":"COMPLETED","sponsor":"Royal Liverpool University Hospital","startDate":"2014-02-01","conditions":"Crohn's Disease","enrollment":59},{"nctId":"NCT01594827","phase":"PHASE2","title":"Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2012-10","conditions":"Cystic Fibrosis","enrollment":29},{"nctId":"NCT02281643","phase":"PHASE2","title":"Concomitant Infections of Mansonella Perstans in Tuberculosis and Buruli Ulcer Disease Patients From Ghana","status":"COMPLETED","sponsor":"Kwame Nkrumah University of Science and Technology","startDate":"2014-10","conditions":"Mansonella Perstans Infection, Buruli Ulcer, Tuberculosis","enrollment":200},{"nctId":"NCT02538224","phase":"PHASE2, PHASE3","title":"Efficacy of Subgingivally Delivered Doxycycline Plus Ketoprofen Gel as an Adjunct to Non-surgical Periodontal Treatment","status":"COMPLETED","sponsor":"Islamic Azad University, Sanandaj","startDate":"2013-07","conditions":"Chronic Periodontitis","enrollment":20},{"nctId":"NCT01668498","phase":"PHASE2","title":"Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2011-05","conditions":"Ras-wildtype Colorectal Cancer","enrollment":88},{"nctId":"NCT01595594","phase":"PHASE3","title":"Comparison Between aPDT and Systemic Doxycycline on Non-surgical Periodontal Therapy in Type 2 Diabetics","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2010-03","conditions":"Periodontal Disease, Type 2 Diabetes","enrollment":30},{"nctId":"NCT02005653","phase":"PHASE4","title":"Alternate Chemotherapy Regimens for the Clearance of W.Bancrofti Infection","status":"COMPLETED","sponsor":"Indian Council of Medical Research","startDate":"2009-02","conditions":"Filarial; Infestation","enrollment":146}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1345,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Experimental: doxycycline","genericName":"Experimental: doxycycline","companyName":"ANRS, Emerging Infectious Diseases","companyId":"anrs-emerging-infectious-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing peptide bond formation. Used for Emerging infectious diseases (investigational indication under ANRS Phase 3 trial).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}